A novel approach to modeling transcriptional heterogeneity identifies the oncogene candidate <i>CBX2</i> in invasive breast carcinoma

Piqué, Daniel G.; Montagna, Cristina; Greally, John M.; Mar, Jessica C.

doi:10.1101/303396

Cited by 2 publications

(2 citation statements)

References 68 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The concept that makes MuTaTo treatment different from existing treatments is the attacking cancer cells receptors from 3 different directions simultaneously at the same time and reflect the scope of hyper-personalized treatment to each patient in the long run. Recently the researchers from the University of Queensland and Albert Einstein College of Medicine jointly developed a statistical approach known as Oncomix [171] to examine breast cancer data from The Cancer Genome Atlas patient database and identified the most promising target known as Chromobox 2 (CBX2) which has been shown to have high levels in aggressive sub-type of breast cancerand therefore could be a potential breast cancer treatment target . Oncomix, captures transcriptional heterogeneity in tumor and identifies oncogene candidates that were over expressed in a subset of breast tumors.…”

Section: Introductionmentioning

confidence: 99%

“…Intronic DNA methylation was strongly associated with the over expression of Chromobox 2 (CBX2), an oncogene. CBX2 over expression in breast tumors was associated with the up regulation of genes involved in cell cycle progression and with poor 5-year survival [171]. This discovery highlights the potential value of the Oncomix approach and will open new therapeutic avenues and move us closer to personalized medicine.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Recent advances in nanotheranostics for triple negative breast cancer treatment

Thakur

Kutty

2019

J Exp Clin Cancer Res

150

View full text Add to dashboard Cite

Triple-negative breast cancer (TNBC) is the most complex and aggressive type of breast cancer encountered world widely in women. Absence of hormonal receptors on breast cancer cells necessitates the chemotherapy as the only treatment regime. High propensity to metastasize and relapse in addition to poor prognosis and survival motivated the oncologist, nano-medical scientist to develop novel and efficient nanotherapies to solve such a big TNBC challenge. Recently, the focus for enhanced availability, targeted cellular uptake with minimal toxicity is achieved by nano-carriers. These smart nano-carriers carrying all the necessary arsenals (drugs, tracking probe, and ligand) designed in such a way that specifically targets the TNBC cells at site. Articulating the targeted delivery system with multifunctional molecules for high specificity, tracking, diagnosis, and treatment emerged as theranostic approach. In this review, in addition to classical treatment modalities, recent advances in nanotheranostics for early and effective diagnostic and treatment is discussed. This review highlighted the recently FDA approved immunotherapy and all the ongoing clinical trials for TNBC, in addition to nanoparticle assisted immunotherapy. Futuristic but realistic advancements in artificial intelligence (AI) and machine learning not only improve early diagnosis but also assist clinicians for their workup in TNBC. The novel concept of Nanoparticles induced endothelial leakiness (NanoEL) as a way of tumor invasion is also discussed in addition to classical EPR effect. This review intends to provide basic insight and understanding of the novel nano-therapeutic modalities in TNBC diagnosis and treatment and to sensitize the readers for continue designing the novel nanomedicine. This is the first time that designing nanoparticles with stoichiometric definable number of antibodies per nanoparticle now represents the next level of precision by design in nanomedicine.

show abstract

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Recent advances in nanotheranostics for triple negative breast cancer treatment

Thakur

Kutty

2019

J Exp Clin Cancer Res

150

View full text Add to dashboard Cite

show abstract

The rise of the distributions: why non-normality is important for understanding the transcriptome and beyond

Mar

2019

Biophys Rev

Self Cite

View full text Add to dashboard Cite

The application of statistics has been instrumental in clarifying our understanding of the genome. While insights have been derived for almost all levels of genome function, most importantly, statistics has had the greatest impact on improving our knowledge of transcriptional regulation. But the drive to extract the most meaningful inferences from big data can often force us to overlook the fundamental role that statistics plays, and specifically, the basic assumptions that we make about big data. Normality is a statistical property that is often swept up into an assumption that we may or may not be consciously aware of making. This review highlights the inherent value of non-normal distributions to big data analysis by discussing use cases of non-normality that focus on gene expression data. Collectively, these examples help to motivate the premise of why at this stage, now more than ever, non-normality is important for learning about gene regulation, transcriptomics, and more.

show abstract

A novel approach to modeling transcriptional heterogeneity identifies the oncogene candidate CBX2 in invasive breast carcinoma

Cited by 2 publications

References 68 publications

Recent advances in nanotheranostics for triple negative breast cancer treatment

Recent advances in nanotheranostics for triple negative breast cancer treatment

The rise of the distributions: why non-normality is important for understanding the transcriptome and beyond

Contact Info

Product

Resources

About